Drug Safety Concerns Could Affect Early Review Stages, FDA's Gottlieb Says
The deputy commissioner reiterates that the agency has not become risk averse when it comes to approvals, however.
The deputy commissioner reiterates that the agency has not become risk averse when it comes to approvals, however.